On October 27, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that two poster presentations taking place at SITC (Free SITC Whitepaper) 2023, the annual meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools to help advance the development of immuno-oncology drugs (Press release, Veracyte, OCT 27, 2023, View Source [SID1234636415]). These tools allow for better characterization of the tumor microenvironment (TME), which can enable new insights into drug response and mechanisms of resistance.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"While immunotherapy drugs such as immune checkpoint inhibitors have been shown to induce remarkable, long-term responses in many cancer types, they remain ineffective for a majority of patients. There is a pressing need to understand drug response so scientists can develop treatments that will be effective for many more patients and types of cancer," said Corinne Danan, Veracyte’s general manager of Biopharma and IVD Services. "These conference presentations will show that Veracyte’s Brightplex and Immunoscore IC tools can offer scientists a clearer view of the tumor microenvironment, as well as data that could inform immuno-oncology drug development."
The following posters will be presented at the SITC (Free SITC Whitepaper) 2023 meeting on Saturday, November 4, 2023:
Title: Deciphering the relationship between lymphocytes and macrophages within the tumor micro-environment using a workflow combining RNA transcripts detection and multiplex IHC on Brightplex
Presenter: Jacques Fieschi, Ph.D., VP, research and development, Veracyte
Abstract: #70
Location: Exhibit Halls A and B1
Title: Regulatory T-cell tumor infiltration improves advanced NSCLC patients’ outcome under ≥ 2nd line anti-PD1/L1monotherapy in The PIONeeR Project
Presenter: Florence Monville, Ph.D., Scientific Head of Collaborative Research Projects at Veracyte
Abstract: #782-C
Location: Exhibit Hall B
In addition, Veracyte will host the following corporate symposium on Friday, November 3, 2023, from 5:10 p.m. to 6:40 p.m. PT:
Title: A Promising Biomarker of Tumor Immunogenicity: Unveiling the Potential of Immunoscore IC (CD8/PDL1)
Presenters: Jérôme Galon, Ph.D. (scientific executive director, Veracyte); Jacques Fieschi, Ph.D. (VP, research and development, Veracyte)
Location: Presentation Stage (Exhibition Floor)